



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Oseltamivir (Standard)

| | |
|--------------------|---|
| Cat. No.: | HY-13317R |
| CAS No.: | 196618-13-0 |
| Molecular Formula: | C ₁₆ H ₂₈ N ₂ O ₄ |
| Molecular Weight: | 312.4 |
| Target: | Influenza Virus |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

Description

Oseltamivir (Standard) is the analytical standard of Oseltamivir. This product is intended for research and analytical applications. Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC₅₀s of 0.67, 0.9, 1.34 and 13 nM, respectively^[1].

REFERENCES

- [1]. O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. *Antiviral Res.* 2005 Oct;68(1):43-8.
- [2]. Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. *Antiviral Res.* 2016 Dec;136:45-50.
- [3]. Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. *Antivir Ther.* 2007;12(3):363-70.
- [4]. Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. *Antimicrob Agents Chemother.* 2008 Nov;52(11):3889-97.
- [5]. Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. *Antiviral Res.* 2010 Oct;88(1):38-44.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA